Tonix Pharmaceuticals Holding Future Growth

Future criteria checks 2/6

Tonix Pharmaceuticals Holding is forecast to grow earnings and revenue by 31.7% and 41% per annum respectively while EPS is expected to grow by 50.1% per annum.

Key information

31.7%

Earnings growth rate

50.07%

EPS growth rate

Biotechs earnings growth	27.2%
Revenue growth rate	41.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	17 Aug 2026

Recent future growth updates

Analysis Article • Aug 13

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

As you might know, Tonix Pharmaceuticals Holding Corp. ( NASDAQ:TNXP ) just kicked off its latest quarterly results...

Recent updates

Analysis Article • Aug 13

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

As you might know, Tonix Pharmaceuticals Holding Corp. ( NASDAQ:TNXP ) just kicked off its latest quarterly results...

Seeking Alpha • Aug 11

Tonix Delivers A Beat, But The Real Test Starts Now

Summary Tonix Pharmaceuticals (TNXP) reported strong 2Q26 results, with $13.5M revenue and early commercial traction for TONMYA, but remains in a spend-to-scale phase. TONMYA prescriptions and refills surged, yet revenue lags due to recent payer coverage; sustained revenue ramp hinges on access translating to reimbursed sales. Operating expenses and cash burn are elevated, with a cash runway into early 2Q27, creating near-term dilution risk despite improving fundamentals. Valuation appears cheap on EV metrics, but equity pricing reflects execution and financing risks; clear proof of scalable, access-driven growth is needed before upgrading from Hold. Read the full article on Seeking Alpha

New Narrative • Aug 10

Fibromyalgia And Lyme Setbacks Will Pressure Margins Yet Long-Term Pipeline Potential Remains

Catalysts About Tonix Pharmaceuticals Holding Tonix Pharmaceuticals Holding develops and commercializes medicines for conditions with unmet medical need, including fibromyalgia, major depressive disorder and Lyme disease prevention. What are the underlying business or industry changes driving this perspective?

Analysis Article • Dec 01

Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analysis Article • Aug 14

Here's Why We're Not Too Worried About Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Situation

NasdaqCM:TNXP 1 Year Share Price vs Fair Value Explore Tonix Pharmaceuticals Holding's Fair Values from the Community...

Earnings and Revenue Growth Forecasts

NasdaqGS:TNXP - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2028	205	-80	-160	-112	4
12/31/2027	116	-153	-205	-139	4
12/31/2026	56	-168	-195	-149	3
6/30/2026	29	-160	-158	-153	N/A
3/31/2026	18	-147	-131	-126	N/A
12/31/2025	13	-124	-103	-100	N/A
9/30/2025	10	-99	-76	-75	N/A
6/30/2025	10	-81	-65	-65	N/A
3/31/2025	10	-132	-60	-60	N/A
12/31/2024	10	-130	-61	-61	N/A
9/30/2024	11	-135	-69	-69	N/A
6/30/2024	12	-149	-76	-73	N/A
3/31/2024	10	-99	-91	-87	N/A
12/31/2023	8	-117	-110	-102	N/A
9/30/2023	4	-123	-114	-102	N/A
6/30/2023	N/A	-124	-121	-102	N/A
3/31/2023	N/A	-123	-132	-100	N/A
12/31/2022	N/A	-117	-146	-98	N/A
9/30/2022	N/A	-112	-167	-98	N/A
6/30/2022	N/A	-102	-156	-88	N/A
3/31/2022	N/A	-98	-141	-86	N/A
12/31/2021	N/A	-92	-111	-76	N/A
9/30/2021	N/A	-80	-81	-67	N/A
6/30/2021	N/A	-73	-80	-69	N/A
3/31/2021	N/A	-64	-69	-60	N/A
12/31/2020	N/A	-52	-57	-49	N/A
9/30/2020	N/A	-46	-45	-41	N/A
6/30/2020	N/A	-42	-33	-33	N/A
3/31/2020	N/A	-34	N/A	-27	N/A
12/31/2019	N/A	-31	N/A	-27	N/A
9/30/2019	N/A	-31	N/A	-27	N/A
6/30/2019	N/A	-28	N/A	-25	N/A
3/31/2019	N/A	-29	N/A	-26	N/A
12/31/2018	N/A	-29	N/A	-24	N/A
9/30/2018	N/A	-24	N/A	-22	N/A
6/30/2018	N/A	-24	N/A	-22	N/A
3/31/2018	N/A	-23	N/A	-21	N/A
12/31/2017	N/A	-21	N/A	-19	N/A
9/30/2017	N/A	-23	N/A	-20	N/A
6/30/2017	N/A	-25	N/A	-23	N/A
3/31/2017	N/A	-30	N/A	-27	N/A
12/31/2016	N/A	-39	N/A	-37	N/A
9/30/2016	N/A	-45	N/A	-44	N/A
6/30/2016	N/A	-50	N/A	-48	N/A
3/31/2016	N/A	-52	N/A	-49	N/A
12/31/2015	N/A	-48	N/A	-43	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TNXP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TNXP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TNXP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TNXP's revenue (41% per year) is forecast to grow faster than the US market (12.9% per year).

High Growth Revenue: TNXP's revenue (41% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TNXP's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/20 22:00
End of Day Share Price	2026/08/20 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tonix Pharmaceuticals Holding Corp. is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Molloy	Alliance Global Partners
Chiara Russo	Brean Capital Historical (Janney Montgomery)
David Buck	B. Riley Securities, Inc.

Tonix Pharmaceuticals Holding Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Consensus revenue estimates decrease by 58%

Forecast to breakeven in 2028

Consensus revenue estimates increase by 21%

Forecast to breakeven in 2028

Price target decreased by 20% to US$54.33

Recent updates

Tonix Pharmaceuticals Holding Corp. Announces Appointment of Seth Lederman as Interim Chief Medical Officer

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Second quarter 2026 earnings: EPS and revenues exceed analyst expectations

Tonix Delivers A Beat, But The Real Test Starts Now

Fibromyalgia And Lyme Setbacks Will Pressure Margins Yet Long-Term Pipeline Potential Remains

Tonix Pharmaceuticals Announces Positive Minutes From Type C FDA Meeting To Discuss Adaptive Phase 2 Field Study Of TNX-4800, A Human, Anti-OspA Monoclonal Antibody, To Prevent Lyme Disease In The US

Tonix Pharmaceuticals Holding Corp. to Report Q2, 2026 Results on Aug 10, 2026

New minor risk - Share price stability

Tonix Pharmaceuticals Holding Corp. Announces Retirement of Gregory M. Sullivan as Chief Medical Officer, Effective August 20, 2026

Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease

Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage

Tonix Pharmaceuticals Enrolls First Patient in Phase 2 Study for Major Depressive Disorder

Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder

Co-Founder recently bought US$59k worth of stock

Tonix Pharmaceuticals Holding Corp. Announces Publication Of Phase 1 Clinical Data Of TNX-1500 Fc-Modified Anti-CD40L Monoclonal Antibody

Tonix Pharmaceuticals Presents Real-World Claims Analysis And Launches TONMYA For Fibromyalgia Treatment

Consensus revenue estimates decrease by 58%

New minor risk - Share price stability

New minor risk - Profitability

Forecast to breakeven in 2028

Consensus revenue estimates increase by 21%

New minor risk - Profitability

Tonix Pharmaceuticals Holding Corp. Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of Tnx-4800

Co-Founder recently bought US$63k worth of stock

New minor risk - Share price stability

Tonix Pharmaceuticals Holding Corp Presents Phase 1 Data And Outlines Planned Adaptive Phase 2 Field Study Of TNX-4800 For Prevention Of Lyme Disease

Tonix Pharmaceuticals Holding Corp Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900

Forecast to breakeven in 2028

Tonix Pharmaceuticals Holding Corp., Annual General Meeting, May 07, 2026

Co-Founder recently bought US$223k worth of stock

Price target decreased by 20% to US$54.33

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Tonix Pharmaceuticals Presents Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Tonix Pharmaceuticals Holding Corp Announces Publication of Clinical Pharmacokinetic Studies of TONMYA and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development

New minor risk - Share price stability

Tonix Pharmaceuticals Holding Corp. Presents Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) At the 2026 Non-Opioid Pain Therapeutics Summit

Tonix Pharmaceuticals Holding Corp. Announces Program Updates on Tnx-4800 Product Candidate for Protection Against Lyme Disease

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $19.999998 million.

Tonix Pharmaceuticals Holding Corp. Appoints Irina Ishak as General Counsel, Effective December 8, 2025

Consensus EPS estimates upgraded to US$13.03 loss

Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?

Tonix Pharmaceuticals Holding Corp. Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA (Cybobenzaprine HCl Sublingual Tablets) as A First-In-Class Fibromyalgia Treatment

Third quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat

Tonix Pharmaceuticals Holding Corp. Presents Data on Tonmya at the 2025 American College of Rheumatology Convergence

Tonix Pharmaceuticals Holding Corp. Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Tonix Pharmaceuticals Holding Corp. Presents Data on TNX-801 Mpox Vaccine at World Vaccine Congress-Europe 2025

Tonix Pharmaceuticals Holding Corp. Appoints Ganesh Kamath as Head of Market Access, Effective September 29, 2025

Tonix Pharmaceuticals Holding Corp. Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of Tnx-2900 (Intranasal Potentiated Oxytocin) in 2026

Tonix Pharmaceuticals Holding Corp. Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Holding Corp. Presents Clinical Data on Tonmya for the Treatment of Fibromyalgia at PAINWEEK 2025

Tonix Pharmaceuticals Holding Corp. Announces FDA Approval of Tonmya (cyclobenzaprine HCl Sublingual Tablets) for the Treatment of Fibromyalgia

Here's Why We're Not Too Worried About Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Situation

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

New major risk - Share price stability

Tonix Pharmaceuticals Holding Corp. to Report Q2, 2025 Results on Aug 11, 2025

Tonix Pharmaceuticals Holding Corp. Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

Tonix Pharmaceuticals Holding Corp. Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

High number of new directors

Tonix Pharmaceuticals Holding Corp. Appoints James ‘Jim’ Hunter to Board of Directors, Effective June 12, 2025

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $150 million.

Consensus revenue estimates increase by 15%

Tonix Pharmaceuticals Holding Corp. Announces First Patient Dosed in Phase 2 Oasis Study of TNX-102 SL for Reduction of Acute Stress Response

Consensus EPS estimates upgraded to US$12.40 loss, revenue downgraded

Co-Founder recently bought US$86k worth of stock

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 88% to US$60.00

Tonix Pharmaceuticals Holding Corp. Presents Data on Potential Mpox Vaccine TNX-801 at World Vaccine Washington 2025